Theralase Technologies Inc. V.TLT

Excellent news! Out first official exposure to ASCO world

[ScienceFirst]

And presentation will be done by Dr. Kulkarni, our Ph. 2 lead investigator, with Princess Margaret Cancer Center's credibility.

2023 will be fun. Pivotal.  Amazingly fun in terms of visibility.

[ScienceFirst]

The poster will include interim clinical data and analysis collected through the enrollment and treatment of patients at all Canadian and US clinical study site by their respective principal investigators for Study II.

[StevenBirch]

That's what stuck out to me, previously they went to these symposiums and talked broadly about PDT or PDT as a way to treat NMIBC but now they are presenting TLT's results and analysis. For those wanting more exposure you got it.

[CancerSlayer]

  Great exposure at the perfect time....couldn't ask for more.  Now, it will be interesting to see "how" the data is presented.  I'm hoping emphasis will be placed not only on the wonderful durable response data as a whole (a total of 29+ patients, including Ph 1b), but also on what an optimized & currently recommended protocol can get you.  That

[enriquesuave]

Excellent news and upcoming exposure.  Perhaps more data as this will be 2.5 -3 months post last update.  3 months later there is the AUA where hopefully they will present even more data with an extra  3 months on top of ASCO presentation.  IMHO   

[Eoganacht]

There's also the 78th Annual Meeting of the Canadian Urological Association (CUA) in Montreal in June. Dr. Kulkarni is co-chair of the scientific program. https://cuameeting.org/ Welcome Message Armen Aprikian CUA President 2022-2023   I invite everyone and their families to a much-anticipated meeting in a city known to all for its cosmopolitan and multicultural nature with

[ScienceFirst]

There are rules for abstracts and presentation.  It's not as one wants! The upcoming presentation should have the same type of data than the Ph. 1b data: https://www.sciencedirect.com/science/article/pii/S2666168322005900 By the way, late abstract deadline for April 29 congress is Feb. 13. For the June 2-6 ASCO conference, that Feb. 12: June 2-6, 2023 • McCormick Place

[rodrabal]

You sound like one of  the people who sold there shares a few day ago. Trying to actual put a negative spin on  this validation of our cancer cure. This is huge news. No matter who much you negative Millie's try to spin it. Give your head a shake !!!!!!!